Three pharmaceutical stocks — Gland Pharma, Caplin Point and Nephrocare Health — are in focus for market watchers today. All three have risen between 50% and 70% so far this year.

All three companies are listed on Indian stock exchanges. Gland Pharma is a Hyderabad-based manufacturer of injectable pharmaceuticals, primarily generic injectables, and is known for its focus on sterile injectables. Caplin Point Laboratories is a Chennai-based pharmaceutical company with a strong presence in emerging markets in Latin America and Africa. Nephrocare Health Services is a kidney-care focused healthcare provider.

The stocks have drawn attention amid developments including USFDA regulatory action and acquisition-related news affecting the pharmaceutical sector, according to the original report.

Regulatory developments involving the US Food and Drug Administration are closely tracked by investors in Indian pharmaceutical companies, as the US is a key export market for the industry and compliance observations such as those tied to good manufacturing practices can affect a company's ability to supply that market. Acquisition activity, likewise, is a recurring theme in the sector as companies seek to expand capabilities and geographic reach.